Danaher (DHR)
(Delayed Data from NYSE)
$272.63 USD
-3.80 (-1.37%)
Updated Sep 20, 2024 04:02 PM ET
After-Market: $272.86 +0.23 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
- YR Estimate
- 12/31/2023
- 12/31/2022
- 12/31/2021
- 12/31/2020
- 12/31/2019
- Revenue - Line of Business (LOBR)
- Total sales: Biotechnology
- 7,172.00
- 8,758.00
- 8,570.00
- 5,276.00
- --
- Revenue - Line of Business (LOBR)
- Total sales: Life Sciences
- 7,141.00
- 7,036.00
- 14,958.00
- 10,576.00
- 6,951.10
- Revenue - Line of Business (LOBR)
- Total sales: Diagnostics
- 9,577.00
- 10,849.00
- 9,844.00
- 7,403.00
- 6,561.50
- Revenue - Geographic (GEOR)
- Geographical region revenue: North America
- 9,961.00
- 13,968.00
- 9,798.00
- 9,011.00
- 7,012.00
- Revenue - Geographic (GEOR)
- Geographical region revenue: Western Europe
- 5,468.00
- 6,910.00
- 5,877.00
- 5,323.00
- 4,057.00
- Revenue - Geographic (GEOR)
- Geographical region revenue: Other developed markets
- 1,270.00
- 1,467.00
- 7,770.00
- 1,299.00
- 1,112.00
- Revenue - Geographic (GEOR)
- Geographical region revenue: High-growth markets
- 7,191.00
- 9,126.00
- 1,357.00
- 6,651.00
- 5,730.00
- Income - Line of Business (LOBI)
- Operating profit: Biotechnology
- 1,909.00
- 3,008.00
- 3,074.00
- --
- --
- Income - Line of Business (LOBI)
- Operating profit: Life Sciences
- 1,209.00
- 1,414.00
- 4,367.00
- 2,054.00
- 1,401.00
- Income - Line of Business (LOBI)
- Operating profit: Diagnostics
- 2,406.00
- 3,436.00
- 2,313.00
- 1,538.00
- 1,134.00
- Income - Line of Business (LOBI)
- Operating profit: Other
- -322.00
- -305.00
- -269.00
- -340.00
- -318.00
- Non Financial / Operating Metric (NFM)
- Total Growth - Organic sales (Core)
- -0.50
- 8.00
- 23.00
- 9.50
- 6.00